J&J dives deeper into bispecifics; SpringWorks announces research deal over Stanford professor's work
Massachusetts biotech F-Star entered a licensing and collaboration agreement with J&J in a deal potentially worth $1.35 billion in milestones.
In exchange for $17.5 million upfront, F-Star announced this morning that the biotech is giving J&J worldwide, exclusive and royalty-bearing license to do R&D and commercialize up to five new bispecific antibodies for J&J therapeutic targets using F-star’s research platforms. J&J will take on all responsibilities for R&D and commercialization under the agreement.
The deal was facilitated by J&J company Johnson & Johnson Innovation, the Big Pharma said.
“We are pleased to collaborate with Janssen and leverage the science of F-star’s proprietary tetravalent bispecific technology,” said F-Star CSO Neil Brewis.
SpringWorks bonds closer with Dana Farber on EGFR
Three months after SpringWorks Therapeutics announced a partnership with Dana-Farber Cancer Institute to investigate one of its cancer molecules, the biotech has announced another partnership — a worldwide license agreement to advance a portfolio of small molecule EGFR inhibitors.
SpringWorks also unveiled a sponsored research agreement with Stanford Medicine for that portfolio. Developed in the laboratory of Stanford Medicine and Dana-Farber professor Nathanael Gray, it was designed to potentially treat EGFR-mutant lung cancers.
The portfolio is designed to address both de novo oncogenic drivers and emerging resistance mutations to existing EGFR inhibitors, according to a company statement — and the most advanced asset in the portfolio is currently in lead optimization.
SpringWorks will pay Dana-Farber an undisclosed amount upfront, along with milestone payments and royalties based on any future net sales. On top of the worldwide license, the SpringWorks deal will fund continuing R&D in Gray’s lab and collaborating labs at Dana-Farber. The agreement is intended to support lead optimization and translational biology efforts as the portfolio moves towards nominating a drug candidate, according to a SpringWorks statement.
Washington DC’s Chase Therapeutics completes milestone-based $20M series B
Washington DC-based Chase Therapeutics revealed the completion of a milestone-based $20M Series B financing, led by Hong Kong investor Chinalink Asia Holdings.
The funds will support Phase III pivotal trials for Chase’s major depressive disorder (MDD) candidate CTC-501 and Parkinson’s disease candidate CTC-413, as well as completing development and validation of a Parkinson’s diagnostic product.
Chase also announced that Javier Romero, Chairman and CEO of Chinalink, will join the Board of Directors.
“Javier Romero brings decades of international business experience to the Board of CTC,” said Chase Therapeutics co-founder and board chair Kathleen Clarence-Smith. “We look forward to working with Javier as we advance our programs in major depressive disorder and Parkinson’s disease.”